Biotech Values

[mcbio]

Three biotechnology companies are trying to catch up to Pfizer with their own JAK drugs - Rigel Pharmaceuticals Inc., Incyte Corp., and Vertex Pharmaceuticals Inc. Pfizer’s pill is the only one in the third and final stage of tests generally needed for U.S. approval.

Quite wrong on two very important fronts. RIGL's drug is a SYK inhibitor, not a JAK inhibitor, thereby affording the company a differentiation angle even if PFE is first to market. Also, AZN has already commenced Phase 3 trials on the SYK inhibitor.